{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:27:42Z","timestamp":1793831262955,"version":"4.6.1"},"reference-count":51,"publisher":"Georg Thieme Verlag KG","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1055\/a-2012-0803","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T23:37:02Z","timestamp":1699659422000},"page":"1498-1506","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonale Hypertonie im Zusammenhang mit Linksherzerkrankungen (Gruppe 2)"],"prefix":"10.1055","volume":"148","author":[{"given":"Max","family":"Wissm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Tichelb\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Dohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurin","family":"Ochs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"M Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"S Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jacc.2017.01.051","article-title":"Pulmonary hypertension in heart failure: Pathophysiology, pathobiology, and emerging clinical perspectives","volume":"69","author":"M Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1801897","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"JL Vachi\u00e9ry","year":"2019","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"M Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"V Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","article-title":"Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: Insights from the Veterans Affairs clinical assessment, reporting, and tracking program","volume":"133","author":"BA Maron","year":"2016","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","article-title":"Mild elevation of pulmonary arterial pressure as a predictor of mortality","volume":"197","author":"P Douschan","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e009729","DOI":"10.1161\/JAHA.118.009729","article-title":"Mild Pulmonary hypertension is associated with increased mortality: A systematic review and meta-Analysis","volume":"7","author":"D Kolte","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"BA Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","article-title":"Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction","volume":"3","author":"RR Vanderpool","year":"2018","journal-title":"JAMA Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ejhf.860","article-title":"Pulmonary hypertension due to left heart disease: Analysis of survival according to the haemodynamic classification of the 2015 ESC\/ERS guidelines and insights for future changes","volume":"20","author":"M Palazzini","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.116.022362","article-title":"Systemic consequences of pulmonary hypertension and right-sided heart failure","volume":"141","author":"S Rosenkranz","year":"2020","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e009047","DOI":"10.1161\/CIRCIMAGING.119.009047","article-title":"Validation of the tricuspid annular plane systolic excursion\/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension","volume":"12","author":"K Tello","year":"2019","journal-title":"Circ Cardiovasc Imag"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.healun.2022.09.005","article-title":"Interest of TAPSE\/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment","volume":"41","author":"C Fauvel","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jcmg.2016.12.024","article-title":"RV Contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: Stratification of clinical phenotypes and outcomes","volume":"10","author":"M Guazzi","year":"2017","journal-title":"JACC Cardiovasc Imag"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamacardio.2019.3345","article-title":"Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function","volume":"4","author":"JH Huston","year":"2019","journal-title":"JAMA Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"A Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00059-019-4823-6","article-title":"Pulmonary hypertension and valvular heart disease","volume":"44","author":"T Tichelb\u00e4cker","year":"2019","journal-title":"Herz"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/heartjnl-2011-300705","article-title":"Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes","volume":"98","author":"O Gaemperli","year":"2012","journal-title":"Heart"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ejhf.864","article-title":"Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"20","author":"E Tigges","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e002358","DOI":"10.1161\/CIRCINTERVENTIONS.114.002358","article-title":"Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification","volume":"8","author":"CJ O\u2019Sullivan","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e019949","DOI":"10.1161\/JAHA.120.019949","article-title":"Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival","volume":"10","author":"J Bermejo","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"J Bermejo","year":"2018","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jacc.2017.05.052","article-title":"Implantable hemodynamic monitoring for heart failure patients","volume":"70","author":"WT Abraham","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"WT Abraham","year":"2016","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"J Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e006863","DOI":"10.1161\/CIRCHEARTFAILURE.119.006863","article-title":"Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: One-year outcomes from the CardioMEMS post-approval study","volume":"13","author":"DM Shavelle","year":"2020","journal-title":"Circ Heart Fail"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)","volume":"22","author":"C Angermann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"ref31","first-page":"2320","article-title":"Treatment response to heart failure management guided by remote pulmonary-artery-pressure-monitoring depends on presence and severity of pulmonary hypertension","volume":"24","author":"B A\u00dfmus","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ehf2.13225","article-title":"Acute pulmonary pressure change after transition to sacubitril\/valsartan in patients with heart failure reduced ejection fraction","volume":"8","author":"JS Tran","year":"2021","journal-title":"ESC Heart Fail"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/ehf2.13952","article-title":"Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension","volume":"9","author":"P Codina","year":"2022","journal-title":"ESC Heart Fail"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/ehf2.12850","article-title":"Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring","volume":"7","author":"W Mullens","year":"2020","journal-title":"ESC Heart Fail"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: Results from the EMBRACE-HF trial","volume":"143","author":"ME Nassif","year":"2021","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: Primary results of the ENABLE trials","volume":"5","author":"M Packer","year":"2017","journal-title":"JACC Heart Fail"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1701886","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"JL Vachiery","year":"2018","journal-title":"Eur Respir J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"RM Califf","year":"1997","journal-title":"Am Heart J"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2018.08.080","article-title":"Pulmonary hypertension associated with left heart disease: Updated recommendations of the Cologne Consensus Conference 2018","volume":"272S","author":"S Rosenkranz","year":"2018","journal-title":"Int J Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.2527","article-title":"Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial","volume":"24","author":"TJ Cooper","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: A randomized controlled trial","volume":"36","author":"E Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"M Guazzi","year":"2011","journal-title":"Circulation"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-capillary, combined, and post-capillary pulmonary hypertension: A pathophysiological continuum","volume":"68","author":"CF Opitz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","article-title":"Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension","volume":"283","author":"T Kramer","year":"2019","journal-title":"Int J Cardiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial","volume":"314","author":"M Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the Soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"B Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"G Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"PW Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"D Bonderman","year":"2013","journal-title":"Circulation"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"TM Dachs","year":"2022","journal-title":"Eur Heart J"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"A phase 3 trial of Sotatercept for the treatment of pulmonary arterial hypertension","volume":"388","author":"MM Hoeper","year":"2023","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2012-0803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T23:38:03Z","timestamp":1699659483000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2012-0803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":51,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,11,10]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2012-0803","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}